Nyxoah SA (NYXH) Stock Analysis

AI analysis of Nyxoah SA (NYXH)

Hold

Nyxoah SA (NYXH) is currently not a strong buy due to its recent performance and analyst downgrades. The stock is trading at $0.88, significantly down from its 52-week high of $5.92, reflecting an 80.44% year-to-date decline. Although the company reported a 21% revenue growth in Q2 2026, its forward P/E is at 0, indicating no earnings growth expected in the near term. The RSI is at 30.874, suggesting it is oversold, but the overall sentiment remains cautious due to recent downgrades from analysts, with Cantor Fitzgerald lowering its price target to $3 from $6. The main risk is the company's ongoing net losses, which reached €32.96 million in Q2 2026, indicating financial instability. Therefore, while there are some positive indicators, the risks outweigh the potential for immediate gains, making it prudent to hold rather than buy at this time.

Valuation Metrics

The current forward P/E ratio for Nyxoah SA (NYXH) is 0.00, compared to its 5-year average forward P/E of -4.19.

Forward P/E

Overvalued

5Y Average P/E

-4.19

Current P/E

0.00

Overvalued

-0.85

Undervalued

-7.52

Forward EV/EBITDA

Fair

5Y Average EV/EBITDA

-3.12

Current EV/EBITDA

-0.42

Overvalued

-0.25

Undervalued

-5.99

Forward P/S

Fair

5Y Average P/S

23.23

Current P/S

1.26

Overvalued

45.85

Undervalued

0.61

Alphio AI Price Scenarios for NYXH

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%NYXH

$9.24

Scenario price

B

Base

Base · 50%NYXH

$7.86

Scenario price

B

Bear

Bear · 25%NYXH

$7.48

Scenario price

Whales holding NYXH

P

Pentwater Capital Management LP

+ HoldingNYXH

-3.88%

3M Return

NYXH FAQ — answered by Alphio AI

Nyxoah SA is a Belgium-based company that produces medical equipment. The company focuses on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The system consists of a neurostimulator, which is implanted close to the nerve of the tongue, as well as an activation chip, which is connected to a disposable patch and is positioned every night by the patient under the chin. It operates in the Healthcare sector.

Nyxoah SA (NYXH) is currently not a strong buy due to its recent performance and analyst downgrades. The stock is trading at $0.88, significantly down from its 52-week high of $5.92, reflecting an 80.44% year-to-date decline. Although the company reported a 21% revenue growth in Q2 2026, its forward P/E is at 0, indicating no earnings growth expected in the near term. The RSI is at 30.874, suggesting it is oversold, but the overall sentiment remains cautious due to recent downgrades from analysts, with Cantor Fitzgerald lowering its price target to $3 from $6. The main risk is the company's ongoing net losses, which reached €32.96 million in Q2 2026, indicating financial instability. Therefore, while there are some positive indicators, the risks outweigh the potential for immediate gains, making it prudent to hold rather than buy at this time.